Navigation Links
Valeant Pharmaceuticals Announces Partnership With National Coalition Against Domestic Violence
Date:10/2/2013

LAVAL, Quebec, Oct. 2, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced a partnership with the National Coalition Against Domestic Violence (NCADV) to help raise awareness of domestic violence. As part of the new domestic violence initiative, Valeant has pledged to donate a portion of sales from all Medicis and Obagi products to the NCADV in support of its initiatives.

"Domestic violence is an issue that affects us all, and in particular the number of women impacted every day is staggering," said J. Michael Pearson, chairman and chief executive officer. "This partnership provides a platform for us to partner with all stakeholders in the industry, from our employees to the medical community to the consumers who use our products, in the battle to end domestic violence. We are excited about the long-term prospects to improve the lives of women through this initiative."

"One in three women experience domestic violence in their lifetime. We can change those numbers dramatically if we all take action," says Rita Smith, executive director of the National Coalition Against Domestic Violence. "October is Domestic Violence Awareness Month and we are thrilled to be announcing our partnership with Valeant in the battle to end domestic violence. Together NCADV and Valeant will make a difference."

For additional information about this initiative, please visit: http://enddomesticviolence.valeant.com.

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology, and branded generics.  More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.

About National Coalition Against Domestic Violence

The National Coalition Against Domestic violence is a world-renowned agency whose work includes coalition building at the local, state, regional and national levels; support for the provision of community-based, non-violent alternatives - such as safe home and shelter programs - for battered women and their children; public education and technical assistance; policy development and innovative legislation; focus on the leadership of NCADV caucuses and task forces developed to represent the concerns of organizationally under-represented groups; and efforts to eradicate social conditions which contribute to violence against women and children.

Contact Information:
Laurie W. Little
949-461-6002
laurie.little@valeant.com

(Logo: http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)


'/>"/>
SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeant Pharmaceuticals Agrees To Acquire AcneFree And Certain Assets From University Medical
2. Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results
3. Valeant Pharmaceuticals To Host Investor Day
4. Valeant Pharmaceuticals To Announce 2012 Second Quarter Results On August 2, 2012
5. Valeant Pharmaceuticals International, Inc. Agrees To Acquire Medicis Pharmaceutical Corporation For $44.00 Per Share In Cash
6. Valeant Pharmaceuticals To Present At UBS Annual Global Life Sciences Conference
7. Valeant Pharmaceuticals Announces Management Change
8. Valeant Pharmaceuticals To Syndicate Incremental Loans
9. Valeant Pharmaceuticals Appoints Howard Schiller To Board Of Directors
10. Valeant Pharmaceuticals Announces Launch of Concurrent Private Offerings of Senior Notes
11. Valeant Pharmaceuticals International, Inc. Announces Pricing Of Concurrent Private Offerings Of Senior Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2017)... EXTON, Pa., July 27, 2017  West Pharmaceutical Services, ... financial results for the second-quarter 2017 and updated financial ... Second-Quarter 2017 Highlights Reported ... 2.5% over the prior-year quarter. Net sales at constant ... 2017 reported-diluted EPS was $0.51, compared to $0.60 in ...
(Date:7/26/2017)... NEW YORK , July 26, 2017 ... Annual Prix Galien USA Award ... honors, the Prix Galien Award recognizes outstanding biomedical and technology ... To qualify, each candidate must be ... the last five years and demonstrate tremendous potential to impact ...
(Date:7/24/2017)... 24, 2017  Diplomat Pharmacy, Inc. (NYSE: ... second quarter 2017 operating results on Monday, August 7, ... follow at 5:00 p.m. ET. ... a live broadcast of the conference call by dialing ... code 51641230 approximately 15 minutes prior to the call. ...
Breaking Medicine Technology:
(Date:7/26/2017)... ... July 26, 2017 , ... An inventor from Salisbury, N.C., ... haven’t yet seen an effective and dignified way to keep leeches in place during ... CUP." , This invention provides an effective way to keep a leech in place ...
(Date:7/26/2017)... ... July 26, 2017 , ... A major challenge many labs ... freeze drying samples and a lengthy freeze dry cycle are a few common challenges ... drying techniques, as well as new accessories and advancements in laboratory freeze dryers that ...
(Date:7/26/2017)... ... July 26, 2017 , ... ... the cloud ; today announced the availability of its latest data protection solution ... use control console for Data Discovery, Classification, Encryption and Digital Rights Management; GTB ...
(Date:7/26/2017)... , ... July 26, 2017 , ... ... or “Isodiol”) a global cannabis innovator, specializing in the development of pharmaceutical and ... from April 1, 2017 to June 30, 2017. Iso International LLC recorded unaudited ...
(Date:7/25/2017)... St. Louis, MO (PRWEB) , ... July 25, 2017 , ... ... (HDIS) in St. Louis, Missouri. The company has achieved record-breaking sales for ... multiple departments over the next 12 months. , The upcoming year offers excitement and ...
Breaking Medicine News(10 mins):